West Pharmaceutical Services (WST) Short term Debt (2009 - 2023)

West Pharmaceutical Services has disclosed Short term Debt across 15 years of filings, most recently posting $2.2 million for Q3 2023.

• Short term Debt for Q3 2023 came in at $2.2 million, changed 0.0% year-over-year; the trailing twelve-month figure through Sep 2023 was $2.2 million (changed 0.0% YoY), and the FY2021 annual result was $44.2 million, up 1821.74% from the prior year.
• Short term Debt came in at $2.2 million for Q3 2023 at West Pharmaceutical Services, roughly flat from $2.2 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $44.2 million in Q3 2021 to a low of $2.2 million in Q1 2022.
• The 5-year median for Short term Debt is $2.3 million (2019), against an average of $7.8 million.
• Across the five-year window, Short term Debt jumped 2200.0% in 2019 and sank 95.02% in 2022, its largest moves.
• West Pharmaceutical Services' Short term Debt stood at $2.3 million in 2019, then changed by 0.0% to $2.3 million in 2020, then soared by 1821.74% to $44.2 million in 2021, then tumbled by 95.02% to $2.2 million in 2022, then changed by 0.0% to $2.2 million in 2023.
• The last three Short term Debt figures came in at $2.2 million (Q3 2023), $2.2 million (Q2 2023), and $2.2 million (Q1 2023), per Business Quant data.